PEDIATRIC CHRONIC KIDNEY DISEASE PROGRAM: study of metabolomics
Not Applicable
- Conditions
- Health Condition 1: N189- Chronic kidney disease, unspecified
- Registration Number
- CTRI/2022/12/048044
- Lead Sponsor
- ICMR
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All children of age 2-18 years with diagnosed chronic kidney disease (all stages of CKD). Attempt shall be made to include 50 children in early stages (1-3) and another 50 in late (4-5) stages of CKD.
For controls: Healthy age and gender matched children attending outpatients for minor illnesses in a 2:1 ratio of cases and controls. A total of 50 controls shall be enrolled.
Exclusion Criteria
Patient presently having acute kidney injury, any bacterial infections or receiving any immunosuppressants, with structural heart disease or undergoing dialysis will be excluded.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method -Levels of serum creatinine, Cystatin C, 25 hydroxy D, parathormone and FGF-23 at baseline and in serial estimations <br/ ><br>-Levels of urinary metabolites Isocitric acid, succinic acid, citric acid, 2oxaloglutarate, Cisaconitate, N-acetylalanine, N-acetylserine, N-acetylthreonine, N-acetyllysine, C glycosylytrptophan, Pseudouridine, O sulfotyrosine at baseline and in serial estimations. <br/ ><br>Timepoint: -Levels of serum creatinine, Cystatin C, 25 hydroxy D, parathormone and FGF-23 at baseline and in serial estimations <br/ ><br>-Levels of urinary metabolites Isocitric acid, succinic acid, citric acid, 2oxaloglutarate, Cisaconitate, N-acetylalanine, N-acetylserine, N-acetylthreonine, N-acetyllysine, C glycosylytrptophan, Pseudouridine, O sulfotyrosine at baseline and in serial estimations. <br/ ><br>
- Secondary Outcome Measures
Name Time Method